Exciting News for COVID-19 Vaccines!

European Commission Grants Marketing Authorization for KOSTAIVE®

What does this mean for individuals?

Global biotechnology leader CSL and sa-mRNA pioneer Arcturus Therapeutics have announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. This is a significant milestone in the fight against the COVID-19 pandemic, as KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission.

KOSTAIVE, which is currently marketed in Japan against COVID-, offers a new and innovative approach to vaccination. The self-amplifying mRNA technology used in KOSTAIVE has shown promising results in clinical trials, with high efficacy rates and a good safety profile. This authorization allows for the distribution and administration of KOSTAIVE to individuals in Europe, providing another valuable tool in the fight against COVID-19.

What does this mean for the world?

The approval of KOSTAIVE by the European Commission is a significant development in the global effort to combat the COVID-19 pandemic. As the first sa-mRNA COVID-19 vaccine to receive authorization in Europe, KOSTAIVE represents a new and advanced technology in the field of vaccination. This approval paves the way for the potential use of self-amplifying mRNA vaccines in other regions of the world, opening up new possibilities for controlling the spread of COVID-19.

Conclusion:

The marketing authorization for KOSTAIVE by the European Commission is a positive step forward in the fight against COVID-19. This innovative vaccine offers new hope for individuals in Europe and around the world, providing a powerful tool for controlling the pandemic. As we continue to navigate these challenging times, developments like these remind us of the importance of scientific innovation and collaboration in overcoming global health crises.